BIOEDGE

Biological EDGE

Buy Now

“Meticulous research. Penetrating analysis. A solid framework for change.”  — Dr. Michael J. Krentz

Biological EDGE

Biohacking Starts With NO

Buy Now

“I used to override my body. Now I listen. The difference is stunning.”— Michael Broder

Biohacking Starts With NO
Testing and Diagnostics

Testing and Diagnostics Library

Every article, presentation, spotlight, and news item we've tagged to Testing and Diagnostics.

AllLibraryArticlesPresentationsSpotlightsNews

Showing 145–157 of 157

Longevity.TechnologyFeb 27, 2026

Measuring intrinsic capacity at scale

Stanford-led THRIVE coalition secured $34.5 million to develop the first FDA-grade Intrinsic Capacity score, a composite measure integrating wearables, blood biomarkers, and functional assessments to predict 20-year health outcomes. This addresses the field's critical gap: the absence of regulatory-grade measurement infrastructure for aging itself, moving beyond disease-specific endpoints toward quantifiable functional decline.

Longevity.TechnologyApr 22, 2026

Inflammation’s statin moment edges closer

BioAge's NLRP3 inhibitor BGE-102 produced marked reductions in inflammatory biomarkers (hsCRP, IL-6, fibrinogen) in Phase 1 testing, positioning upstream inflammasome inhibition as a potential scalable approach to chronic inflammation management. This advances a field that has lacked convenient, long-term preventive options despite growing evidence that inflammation drives cardiovascular and age-related disease.

Longevity.TechnologyMar 24, 2026

Basecamp Research’s new gene atlas could speed longevity R&D

Basecamp Research's Trillion Gene Atlas expands genetic reference data 100-fold across 100 million species to improve AI drug discovery models for aging. The underlying premise is that current AI systems underperform not due to model limitations but because they train on narrow, repetitive biological data insufficient for solving complex, multisystem conditions like aging.

Longevity.TechnologyMar 23, 2026

NeuroRPM to provide AI monitoring for Annovis Parkinson’s trial

NeuroRPM's FDA-cleared wearable platform will continuously monitor motor symptoms in a 500-participant Parkinson's disease trial, using Apple Watch data to measure bradykinesia, tremor, and dyskinesia with algorithmic precision. This represents the first FDA-cleared AI device for real-world Parkinson's symptom tracking, enabling detection of treatment response at granularity not achievable through standard clinical assessments alone.

Longevity.TechnologyMar 30, 2026

Insilico, Tenacia expand AI-driven CNS collaboration

Insilico Medicine and Tenacia Biotechnology are expanding their AI-driven collaboration to design small-molecule therapies for central nervous system disorders, with a focus on blood-brain barrier penetration. This partnership demonstrates how generative AI can accelerate drug discovery for neurological conditions, including a candidate targeting NLRP3 inflammation that has cleared FDA review for Parkinson's disease trials.

Wiley Aging CellFeb 13, 2026

Telomere Shortening Drives Atrial Fibrillation Through VCAM‐1 Mediated Atrial Electrical and Structural Remodeling

Telomere shortening drives atrial fibrillation through VCAM-1 upregulation, which promotes atrial fibrosis and electrical dysfunction. Blocking VCAM-1 reverses these changes and reduces AF susceptibility by 30%, identifying a mechanistic pathway linking cellular aging to arrhythmia risk.

Nature - npj AgingApr 21, 2026

Mild cognitive impairment cases affect the predictive power of Alzheimer’s disease diagnostic models using routine clinical variables

Mild cognitive impairment (MCI) cases substantially reduce the predictive accuracy of Alzheimer's disease diagnostic models built on routine clinical variables. This finding challenges the assumption that standard biomarkers and clinical assessments alone can reliably stratify progression risk in early cognitive decline.

LT WireMar 18, 2026

Cognito Therapeutics presents Spectris data in Alzheimer’s disease

Cognito Therapeutics presented clinical and biomarker data supporting Spectris, a non-invasive neurostimulation therapy using synchronized light and sound to modulate gamma frequency brain waves in Alzheimer's disease. Prior studies showed preserved brain structure, slowed cognitive decline, and reduced atrophy compared with controls, with favorable safety profiles and no amyloid-related imaging abnormalities.

Wiley Aging CellFeb 2, 2026

Multi‐Omics Analysis of Human Blood Cells Reveals Unique Features of Age‐Associated Type 2 CD8 Memory T Cells

Aging drives accumulation of a distinct CD8 T cell population lacking CXCR3 that exhibits Th2-skewed transcriptional and epigenetic programming. This shift correlates with increased risk for asthma, chronic liver disease, and type 2 diabetes, suggesting age-related immune dysregulation follows a predictable molecular trajectory.

SAGE Research on AgingMar 26, 2026

Developing a Genetic Algorithm-Based Frailty Index for China Health and Retirement Longitudinal Study

Researchers developed a genetic algorithm-based frailty index using nine years of longitudinal data from the China Health and Retirement Longitudinal Study to predict mortality and falls risk in aging adults. This computational approach identifies which physiological and functional markers most reliably indicate vulnerability to adverse outcomes, providing a data-driven alternative to subjective clinical assessment.

Wiley Aging CellApr 6, 2026

Serum‐Derived Extracellular Vesicles as Biological Indicator of Mobility Resilience in Older Adults

Serum extracellular vesicles carry distinct molecular signatures—small noncoding RNAs and mitochondrial proteins—that differentiate older adults with preserved mobility from those with age-related gait decline. These circulating vesicles appear to mediate brain-muscle communication and may serve as noninvasive biomarkers for identifying individuals at risk of functional decline.

Longevity.TechnologyFeb 16, 2026

Nautilus expands single-molecule proteomics into Parkinson’s

A $1.6 million collaboration between Nautilus Biotechnology, Weill Cornell Medicine–Qatar, and The Michael J Fox Foundation aims to detect alpha-synuclein proteoforms at single-molecule resolution to enable earlier Parkinson's disease diagnosis and subtype distinction. Current protein measurement tools average signals across millions of molecules, obscuring the structural variants that may drive disease progression and therapeutic response differently across individuals.

Nature AgingMar 11, 2026

Microglia protein profiles in CSF across Alzheimer’s disease clinical stages

Analysis of microglial proteins in cerebrospinal fluid identifies distinct molecular signatures across Alzheimer's disease stages, offering potential biomarkers for earlier detection and disease progression tracking. These markers reflect immune cell activation patterns that precede symptomatic decline, enabling more precise stratification of disease trajectory.